CHRNA7 and Cognitive impairment: In two phase III clinical trials (ClinicalTrials.gov Identifier: NCT01716975 and NCT01714661) for the treatment of cognitive impairment in schizophrenia, encenicline (a selective α7nAChR partial agonist) failed to meet the co-primary endpoints for improved cognitive and clinical function [86].